Diane Warren

Harvard University — United States

Medicine · Health Sciences

22h-index4.8kcitations77works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(28), Chronic Lymphocytic Leukemia Research(24), Protein Degradation and Inhibitors(22), Lymphoma Diagnosis and Treatment(16), Chronic Myeloid Leukemia Treatments(9)

Publications77 total

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
Blood Cancer Journal·2021· 13 citedOpen Access
Coda
Edinburgh University Press eBooks·2020
Coda: Rereading Orphanhood
Edinburgh University Press eBooks·2020
‘The accumulated and single’: Modernity, Inheritance and Orphan Identity
Edinburgh University Press eBooks·2020· 1 cited
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Blood·2019· 11 cited
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
American Journal of Hematology·2019· 60 citedOpen Access
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Blood·2018· 20 cited
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
Leukemia·2018· 58 cited
Untitled
The Modern Language Review·2018
‘the fadged up ends of discontent’ 1
2017
Dying to be an Individual
2017
CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
2017
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
Blood·2016· 318 citedOpen Access
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations
British Journal of Haematology·2015· 82 citedOpen Access
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
New England Journal of Medicine·2015· 914 citedOpen Access
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
Blood·2014· 4 cited
Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia
Blood·2014· 4 cited
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
Blood·2014· 177 citedOpen Access
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Blood·2014· 183 citedOpen Access
Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Blood·2013· 5 cited
page 1 of 4Next →

Frequent Co-authors

Paul G. Richardson(41), Irene M. Ghobrial(38), Kenneth C. Anderson(37), Nikhil C. Munshi(26), Robert Schlossman(24), Stacey Chuma(19), Jacob P. Laubach(18), Steven P. Treon(17), Edie Weller(16), Renee Leduc(14), Janet Kunsman(12), Brianna Harris(11), Amy Sam(11), Deborah Doss(10), Constantine S. Mitsiades(10), Jeffrey Matous(10), Teru Hideshima(8), Meghan Rourke(8), Andrzej Jakubowiak(7), Sundar Jagannath(7)